Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Vascular Endothelial Growth Factor A. Found 15 abstracts

Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. Clinical advances in hematology & oncology : H&O. 2018 Oct;16(10):677-86.
Fu J, Zhang J, Gong Y, Testa CL, Klein-Szanto AJ. Regulation of HIF-1 Alpha by the Proprotein Convertases Furin and PC7 in Human Squamous Carcinoma Cells. Molecular Carcinogenesis. 2015 Sep;54(9):698-706.   PMCID: 4101078
Lee S, Goldfinger LE. RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells. FASEB J. 2014 Sep;28(9):4158-68.   PMCID: 4139904
Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50.   PMCID: 4175044
Obeid E, Nanda R, Fu YX, Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol. 2013 Jul;43(1):5-12.   PMCID: PMC3742164
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr;129(1):86-91.   PMCID: PMC 3712785
Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer. 2010 Jun;46(9):1537-53.   PMCID: PMC2927957
Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2009 Mar;112(3):583-9.   PMCID: PMC2858218
Golovine K, Uzzo RG, Makhov P, Crispen PL, Kunkle D, Kolenko VM. Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway. The Prostate. 2008 Sep 15;68(13):1443-9.
Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM. Diverse effects of zinc on NF-{kappa}B and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis. 2006 Oct;27(10):1980-90.
Berger AC, Watson JC, Ross EA, Zalatoris A, Hoffman JP. Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. Am Surg. 2004 Feb;70(2):169-73; discussion 173-4.
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Cancer Research. 2004 Dec;10(23):8048-58.
Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W, Rubin SC, Coukos G. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res. 2003 Jul 15;63(14):4225-31.
Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun. 2003 Apr 18;303(4):1169-78.
Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003 Jun 15;63(12):3403-12.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Vascular Endothelial Growth Factor A

Vascular Endothelial Growth Factor A metabolism Female pathology genetics drug therapy Male Pathologic Neovascularization Ovarian Neoplasms pharmacology blood supply Neoplastic Gene Expression Regulation Mice physiology Angiogenesis Inhibitors antagonists & inhibitors Vascular Endothelial Growth Factors Tumor Cell Line Disease-Free Survival Endothelial Growth Factors biosynthesis Middle Aged therapeutic use blood Intercellular Signaling Peptides and Proteins Human Non-US Gov't Support Lymphokines Aged Indoles Vascular Endothelium Messenger RNA methods Interleukin-8 Antineoplastic Combined Chemotherapy Protocols Prostatic Neoplasms Adenocarcinoma US Gov't Support-PHS Neoplasm Proteins Matrix Metalloproteinase 9 analogs & derivatives Apoptosis Kidney Neoplasms 80 and over Aged Carcinoma Signal Transduction Heterologous Transplantation alpha Subunit Hypoxia-Inducible Factor 1 Immunohistochemistry Cultured Tumor Cells RNA Interference NF-kappa B Adult Breast Neoplasms adverse effects administration & dosage Zinc therapy secretion Neoplasm RNA Pyrroles Antineoplastic Agents Angiopoietin-2 drug effects Interleukin-6 Biological Models Von Hippel-Lindau Tumor Suppressor Protein Receptor Protein-Tyrosine Kinases Furin Up-Regulation antagonists & Protein-Tyrosine Kinases 129298-91-5 (O-(chloroacetylcarbamoyl)fumagillol) Clear Cell Adenocarcinoma Carboplatin 0 (Antineoplastic Combined Chemotherapy Protocols) Topotecan 85622-93-1 (temozolomide) Cytokine Receptor gp130 Uterine Cervical Neoplasms enzymology growth factors Dactinomycin Morpholines Fibroblast Growth Factor Receptor-Type 1 proprotein convertases Hypoxia-Inducible Factor 1 Drug Dose-Response Relationship Squamous Cell Carcinoma Neoplasm Antigens pk inhibitors epidemiology Angiogenesis Inducing Agents Western Blotting 123948-87-8 (Topotecan) Risk Factors Extracellular Matrix Transcription Factor AP-1 0 (Vascular Endothelial Growth Factor A) MAP Kinase Signaling System Rats pharmacokinetics surgery Small Interfering RNA Recombinant Fusion Proteins aa [Analogs & Derivatives] 4342-03-4 (Dacarbazine) Transcriptional Activation Chelating Agents Inbred F344 Rats Protein Biosynthesis Local Neoplasm Recurrence Fallopian Tube Neoplasms mortality Catalytic Domain [Pharmacokinetics] Nude Rats Proportional Hazards Models Dacarbazine Pancreatic Neoplasms furin Tumor Biomarkers Genetic Vectors Cell Adhesion Nude Mice Ethylenediamines Sesquiterpenes Subtilisins angiogenesis Reverse Transcriptase Polymerase Chain Reaction Treatment Outcome Phosphatidylinositol 3-Kinases cytology Cell Hypoxia Experimental Melanoma Analysis of Variance Protein Isoforms Transformed Cell Line Brain Neoplasms physiopathology Cell Division Lewis Lung Carcinoma Aorta GTPase-Activating Proteins Paracrine Communication ad [Administration & Dosage] Prognosis Pc7 Predictive Value of Tests
Last updated on Thursday, April 02, 2020